GOLD COAST, Australia, 23rd October 2019: Today, DermaSensor, the medical device company that aims to enable healthcare professionals to efficiently check for skin cancer, demonstrates its revolutionary skin cancer detection technology concept at the Rural Medicine Australia Conference on the Gold Coast.
This annual conference and research/scientific health forum is hosted by the Australian College of Rural and Remote Medicine (ACRRM) and the Rural Doctors Association of Australia (RDAA). Nearly 900 rural doctors, medical students and other rural health stakeholders from across the country attended the event.
Rural Medicine Australia 2019 aims to educate and inform rural health professionals including junior doctors, students, educators, academics, and medical practitioners who are passionate about generalist medicine in rural and remote communities.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor Team are in attendance conducting market research into the use-case for the DermaSensor device concept, a world-first technology designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.
“We are pleased to return for the second year in a row to present DermaSensor’s technology concept, to further understand how it might one day help rural doctors quickly and effectively check for skin cancer,” explains Kevin. “We look forward to answering questions and demonstrating a skin health service that’s efficient, accurate and affordable,” he says.
This exciting breakthrough uses Elastic Scattering Spectroscopy – a technology pioneered at Boston University and University College London that uses light to evaluate cellular and subcellular structures of the skin.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. This low-cost, easy-to-use device enables healthcare providers and patients to access fast, accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.
DermaSensor aims to improve the way general practitioners assess the skin. The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. This provides an immediate, objective result that’s typically more accurate than visual assessment alone.
Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.